Vienna, Austria,
2020-06-12 12:12
(339 d 03:11 ago)

Posting: # 21531
Views: 652

 Bracketing Approach [Power / Sample Size]

Dear all,

two participants of the recent survey commented that the “Bracketing Approach” (e.g., non-superiority of Cmax, non-inferiority of Cmin)* and testing for equivalence of AUC is not available in the software they are using most (without naming it).

In PowerTOST it is implemented (see its vignette for examples). Since the CV of AUC is generally lower than the ones of Cmax/Cmin it will not drive the sample size.

  • EMA, CHMP. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. London; 20 November 2014. EMA/CHMP/EWP/280/96 Rev1.
    “5.1.1. Waiving of therapeutic studies
    Cmax,ss for the new MR formulation is below or equivalent to the Cmax,ss for the approved formulation and Cmin,ss for the MR formulation is above or equivalent to the Cmin,ss of the approved formulation.”

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 Admin contact
21,462 posts in 4,487 threads, 1,514 registered users;
online 25 (0 registered, 25 guests [including 12 identified bots]).
Forum time: Monday 15:24 CEST (Europe/Vienna)

Garbage in, garbage out.
It’s very very simple.    Anders Fuglsang

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz